Q-omics provides the consensus-scored SEPHS2P1 profile across patient tissues and cancer cell-line models. SEPHS2P1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SEPHS2P1 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, SEPHS2P1 RNA expression shows 6,606 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, and STAD as cancer lineages where SEPHS2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPHS2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPHS2P1 survival associations across molecular data types. SEPHS2P1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPHS2P1 RNA expression–survival associations across cancer types. High SEPHS2P1 expression shows unfavorable associations in LUAD, CESC, DLBC, KICH, SARC and TGCT. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SEPHS2P1 RNA expression.
This table summarizes SEPHS2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SEPHS2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPHS2P1 shows higher tumor expression in STAD, COAD, LUAD, LUSC, LIHC and KICH. The STAD box plot shows higher SEPHS2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .013).
This table shows molecular features associated with SEPHS2P1 in patient tissues and cancer cell lines. In patient samples, SEPHS2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
